Precigen(PGEN)
GERMANTOWN, MDBiotechnology
Focus: Precigen is a public biotechnology company specializing in cell and gene therapy for oncology, rare diseases, and metabolic conditions. The company operates at the early-stage development level with a lean commercial footprint focused on rare respiratory disease.
Profile data last refreshed 10h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
8-3 this month
Stable — net -3 jobs in 30d
6 added, 9 removed. Backfill posture.
Should You Work at Precigen?
AI assessmentPrecigen suits early-stage biotech scientists and clinical developers willing to accept high clinical and financial risk in exchange for meaningful gene/cell therapy exposure and potential upside if pipeline advances.
Why Work Here
- Exposure to cutting-edge gene and cell therapy modalities (CAR-T, oncolytic immunotherapy) at a public company with public market validation
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
8 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$6M
Pipeline & Clinical Trials
INXN-4001
Heart FailureClinical Trials (1)
NCT03409627Novel INXN-4001 Triple Effector Plasmid in Heart Failure
Phase 1Help build intelligence for Precigen
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.